Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Trial of Neoadjuvant Combination of Ficerafusp Alfa, Pembrolizumab, and SBRT for Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)

NCT07552558 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.

NCT NCT07552558
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07552558 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Trial of Neoadjuvant Combination of Ficerafusp Alfa, Pembrolizumab, and SBRT for Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
Lead sponsor
Washington University School of Medicine
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
November 30, 2033
Enrollment
45 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck squamous cell carcinoma, hpv-negative squamous cell carcinoma